In September 2025 the last two Rite Aid stores, one on Bainbridge Island in Washington and one in Bend, Oregon, closed their doors. The chain was 63 years old. Its second bankruptcy in under two years ended in full liquidation, with prescription files sold off to CVS, Walgreens, Albertsons and Kroger.
That is the headline event, but it is not the whole change. In the same stretch, Sycamore Partners took Walgreens private in a transaction valued at roughly 10 billion dollars, and the restructuring that followed closed around 500 Walgreens stores by the end of 2025, with fewer than 100 more planned for 2026. CVS closed roughly 270 of its own locations in 2025 while acquiring more than 600 former Rite Aid stores across three states.
Count it up and the American drug channel lost one of its three national chains, took the second one off the public markets, and left the third one running a large integration project.
Fewer doors is not the interesting part
Beauty coverage tends to read store closures as lost distribution. For a mass brand it is worse than that and also better than that.
Worse, because the buyer list got shorter. A brand that used to have three national chain conversations now has two, and one of those is a private-equity-owned company running to a cost plan. Concentration in the buying room is not a neutral development for a supplier with no leverage.
Better, because the doors that survived are the productive ones, and the retailers that kept them have a merchandising problem they cannot solve with pharmacy alone. A front end that exists to fill the space between the door and the pharmacy counter is a cost. A front end that people come in for is a business. Beauty is the category historically asked to make that difference, and the last twelve months read like the chains asking it again.
What is walking into the surviving doors
Three data points from the last two months, none of them announcements about strategy, all of them about shelf.
In June 2026, Lactomedi, a Korean microbiome-focused feminine care brand, launched in more than 4,000 CVS stores. Before that it was an online product, with roughly 300,000 units of its probiotic gel sold in 2025. K-beauty's route into American mass retail used to run through sheet masks and serums. This one ran through intimate wellness, which is a category chain drug is structurally better at selling than specialty beauty is.
In July 2026, Beauty Creations, founded in 2016 and now distributed in more than 47 countries, announced its arrival at CVS, starting on CVS.com with a rollout to selected stores. The founder's line about starting at flea markets is the sort of quote that travels, but the interesting part is the assortment: lip, brow, pressed powder, liquid blush. Color, at mass price points, in a channel that spent a decade being told color was migrating to specialty.
And underneath both, e.l.f. Beauty finished fiscal 2026 with net sales up 25 percent year over year and a fourth quarter of 449.3 million dollars, up 35 percent. Its share of the US mass color cosmetics market sits around 12 percent, second by dollars and first by units, against roughly 4.5 percent five years ago.
Mass beauty is not surviving the channel's contraction. It is growing through it.
The consequence for anyone trying to get in
Concentration changes the mechanics of entry, not just the odds. When the channel had more owners, a brand could build a regional proof case and use it as leverage. With the buyer list this short, the proof case has to be portable on day one: margin, case pack, planogram fit, a velocity number from somewhere else.
That is also why the meetings format at NACDS Total Store Expo, which opens in Boston this weekend, is worth more attention than the floor. Ten minutes in front of a buyer who now covers thousands of doors is not a networking opportunity, it is the distribution decision itself, compressed. We walked through how that room works.
The shelf did not get bigger. The number of people who decide what goes on it got smaller, and beauty is what they are deciding about.
